Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Ionis Pharmaceuticals Completes $770M Convertible Notes Offering
- Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval
- Arrowhead price target raised to $45 from $29 at Morgan Stanley
- Ionis Pharmaceuticals announces $700M convertible senior notes offering